A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian ciprofloxacin health economic study group

Chest

Volumn 113, Issue 1, 1998, Pages 131-141

  Grossman, Ronald ^a   Mukherjee, Jayanti ^a   Vaughan, David ^a   Eastwood, Clive ^a   Cook, Richard ^a   LaForge, Jacques ^a   Lampron, Noel ^a  

^a NONE

Author keywords

Acute exacerbations of bronchitis; Ciprofloxacin; COPD; Health economics; Quality of life; Risk stratification

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFALEXIN; CEFIXIME; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; PENICILLIN V; PIVAMPICILLIN; TETRACYCLINE;

ACUTE DISEASE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; DRUG FATALITY; DYSPNEA; FEMALE; HEALTH CARE COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT DISEASE; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 0031974453     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.1.131     Document Type: Article

References (27)

1. Morrell DC. Expressions of morbidity in general practice. BMJ 1971; 2:454-58
2. Woolcock AJ. Epidemiology of chronic airways disease. Chest 1989; 96(suppl):302S-06S
3. Anthonisen NR, Manfreda J, Warren PW, et al. Antibiotic therapy in exacerbations of chronic obstructive lung disease. Ann Intern Med 1987; 106:196-204
4. Jorgensen JH. Update on mechanisms and prevalence of anti-microbial resistance in Haemophilus influenzae. Clin Infect Dis 1992; 14:1119-23
5. Doern GV. Trends in anti-microbial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99(suppl 6B):3S-7S
6. Chodosh S, Tuck J, Stottmeier KD, et al. Comparison of ciprofloxacin with ampicillin in acute infections exacerbations of chronic bronchitis. Am J Med 1989; 87(suppl 5A):107S-12S
7. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276:1339-41
8. Crossman RF, Beaupre A, LaForge J. et al. A prospective, randomized, parallel, single-blind comparison of oral ciprofloxacin with oral trimethoprim-sulfamethoxazole in the treatment of respiratory infections for patients with chronic obstructive lung disease. Drug Invest 1994; 8:110-17
9. Cook RJ, Ng ETM, Mukherjee J, et al. Two-state mixed renewal processes for chronic disease. Stat Med (in press)
10. Ball P, Harris JM. Lowson D, et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88:61-8
11. Balter MS, Hyland RH, Low DE, et al. Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994; 151:7-23
12. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics 1993; 3:354-61
13. Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. PharmacoEconomics 1996; 9:535-59
14. Tugwell P, Bennett K, Sackett D. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis 1985; 38: 339-51
15. Ball AP, Tillotson GS. Lower respiratory tract infection therapy - the role of ciprofloxacin. J Int Med Res 1995; 23:315-27
16. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113:465-74
17. Wilson R, Tillotson G, Ball P. Clinical studies in chronic bronchitis: a need for better definition and classification of severity. J Antimicrob Chemother 1996; 37:205-08
18. Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med 1975; 292:563-70
19. Berry DG, Fry J, Hindley CP, et al. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1960; 1:137-39
20. Pines A, Raafat H, Plucinski K, et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968; 2:735-37
21. Elmes PC, King TKC, Langlands JHM, et al. Value of anipicillin in the hospital treatment of exacerbations of chronic bronchitis. BMJ 1965; 2:904-08
22. Peterson ES, Esmann V, Honcke P, et al. A controlled study of the effect of treatment on chronic bronchitis: an evaluation using pulmonary function tests. Acta Med Scand 1967; 182:293-305
23. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis: a controlled study using tetrucycline. Ann Intern Med 1982; 97:18-21
24. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-83
25. Testa MA, Simonson DC. Assessment of Quality-of-life outcomes. N Engl J Med 1996; 334:835-40
26. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-81
27. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982; 1:61-80